<DOC>
	<DOCNO>NCT00674323</DOCNO>
	<brief_summary>This study aim compare efficacy ranibizumab verteporfin PDT combination treatment verteporfin PDT monotherapy vs.ranibizumab monotherapy alone achieve complete regression polyp patient symptomatic macular polypoidal choroidal vasculopathy .</brief_summary>
	<brief_title>Efficacy Safety Verteporfin Added Ranibizumab Treatment Symptomatic Macular Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients must give write informed consent assessment perform . Male Female patient ≥18 yrs age Patients willing able comply study procedure Inclusion criterion study eye : BCVA letter score 7324 ( approximately 20/40 20/320 Snellen equivalent ) use ETDRS visual acuity chart measure 4 meter PCV diagnosis confirm Central Reading Center Greatest Linear Dimension ( GLD ) total lesion area &lt; 5400 µm ( ~9 Macular Photocoagulation Study Disc Areas ) Women childbearing potential use one reliable contraception method Pregnant nursing ( lactate ) woman History hypersensitivity allergy fluorescein indocyanine green ( ICG ) , clinically significant drug allergy know hypersensitivity therapeutic diagnostic protein product , study drug component Patient history porphyria Systemic medication know toxic lens , retina , optic nerve History might affect interpretation result study , render patient high risk treatment complication Use investigational drug within 30 day randomization Exclusion criterion study eye : Concomitant conditions/diseases : Presence angioid streak , macular fibrosis , presume ocular histoplasmosis syndrome , pathologic myopia ( 8 Diopters ) Active ocular inflammation infection Uncontrolled glaucoma Ocular disorder may confound interpretation study result Prior Ocular treatment : Prior Verteporfin PDT , externalbeam radiation , laser photocoagulation , macular surgery , transpupillary thermotherapy Prior local treatment Pegaptanib , Ranibizumab , Bevacizumab antiangiogenic compound investigational treatment eye systemic use bevacizumab within 90 day prior randomization History intraocular surgery include par plana vitrectomy intraocular hemorrhage displacement allow exception uncomplicated cataract surgery allow within 60 day prior screen Ocular condition require chronic concomitant therapy within 90 day prior randomization topical , ocular , systemically administer corticosteroid herbal medication know contain steroidlike component Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Polypoidal choroidal vasculopathy</keyword>
	<keyword>PCV</keyword>
	<keyword>Age-related macular degeneration ( AMD ) variant</keyword>
	<keyword>vision</keyword>
	<keyword>polyp</keyword>
	<keyword>indocyanine green angiography</keyword>
	<keyword>verteporfin</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>photodynamic therapy</keyword>
</DOC>